Detail akcie Repare Therap Rg online

Business Summary: Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Repare Therapeutics Inc revenues increased 5% to $53.5M. Net loss decreased 10% to $84.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 20% to $93.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.23 to -$2.00.